AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with carboplatin and paclitaxel followed by IMFINZI monotherapy has been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).1 The approval by the Food and Drug Administration (FDA) was based on the results of a prespecified exploratory subgroup analysis by MMR status in the DUO-E Phase III trial. Results from DUO-E w.

IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

ASML Hld

Novo Nordisk

Wall Street loves coming up with cute little phrases, whether that be “FANG” or the more recent Magnificent 7. However, Thornburg portfolio manager Nicholas Anderson would like investors to be familiar with a new concept: targeting the best Fantastic 5 stocks for potentially blistering upside.

3 Best Stocks to Buy From the Fantastic 5

AstraZeneca said its blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).

AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer

Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FARXIGA® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older.1 The FDA approval was based on positive results from the pediatric T2NOW Phase III trial.2 FARXIGA was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycemic control.1 Ruud Dobber, Executive Vice President, BioP.

FARXIGA approved in the US for the treatment of pediatric type-2 diabetes

In the closing of the recent trading day, Astrazeneca (AZN) stood at $80.21, denoting a +0.24% change from the preceding trading day.

Astrazeneca (AZN) Advances But Underperforms Market: Key Facts

The FDA grants priority review to AstraZeneca's (AZN) Tagrisso for treating patients with unresectable, stage III EGFR-mutated lung cancer. A decision is due in the fourth quarter of 2024.

AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag

LVMH Moet Hennessy Louis Vuitton

SAP SE

Five mega companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks make this list.

Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT). If approved, TAGRISSO will be indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 (L858R) mutations. The Food and Drug Ad.

TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

Caterpillar

Coca-Cola

Today, we discuss three must-own stocks as major Wall Street indices reach new highs. The rise in share prices of technology stocks and supportive economic data hinting at potential Federal Reserve policy easing have contributed to investor optimism.

The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now

Drugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.

Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big

ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world's first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the closing of a Series A extension round with new investor AstraZeneca (LSE/STO/Nasdaq: AZN). AstraZeneca joins existing investors from GE Healthcare, Mayo Clinic, Eclipse Ventures, Fox Chase Cancer Center, Echo Global Granger Management Mercy Health, and the University of Missouri as Nucleus expands devel.

Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca Investment

In a Tuesday interview with CNBC's Jim Cramer, AstraZeneca CEO Pascal Soriot explained why the drug maker believes it can almost double revenues by the end of the decade. AstraZeneca announced in late May it plans to raise revenues from $45.8 billion in 2023 to $80.billion in 2030, as well as release 20 new drugs by then.

Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md. , June 4, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its first time in human investigator-initiated trial (IIT) of C-CAR031 in connection with the Company's oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024

Reaction to AstraZeneca PLC (LSE:AZN)'s presentations at the annual American Society of Clinical Oncology conference was broadly positive following of sessions with analysts and clinicians. Eye-catching was the claim around Tagrisso, which was hailed as "practice changing" when administered to lung cancer with a certain mutation of the disease.

AstraZeneca: ASCO feedback positive

In the latest trading session, Astrazeneca (AZN) closed at $78.99, marking a +1.24% move from the previous day.

Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know

Amgen

Viking Therapeutics

Eli Lilly and Novo Nordisk aren't the only ones making anti-obesity drugs. Amgen, AstraZeneca, and Viking Therapeutics have credible candidates.

The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumors have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to placebo after CR.

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following standard-of-care concurrent chemoradiotherapy (cCRT). These results will be present.

IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

WILMINGTON, Del.--(BUSINESS WIRE)--Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as I.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy.

ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy

AbbVie

Vertex Pharmaceuticals

AbbVie covers all the bases for investors -- income, value, and growth. AstraZeneca is an inexpensive stock that has solid growth opportunities.

3 No-Brainer Stocks to Buy in June

Compugen

Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening the assessment of rilvegostomig reinforces Compugen's partnering strategy to expand opportunities for its pipeline Compugen to receive $5 million milestone payment from AstraZeneca HOLON, Israel , May 30, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody.

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AstraZeneca has been a top-performing stock since 2014. Management recently rolled out an $80 billion sales target for 2030.

This Pharma Stock Is Poised to Keep Outperforming the S&P 500

GlaxoSmithKline

Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.

News for AstraZeneca Stock (AZN)